Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

Journal of neuro-oncology - 1 Dec 2007

El Hallani Soufiane, Marie Yannick, Idbaih Ahmed, Rodero Mathieu, Boisselier Blandine, Laigle-Donadey Florence, Ducray François, Delattre Jean-Yves, Sanson Marc

Abstract excerpt

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Prognosis

Share to Proto-Oncogene Proteins c-mdm2

Share to Reference Values

Share to Survival Analysis

Source

Identifiers

PMID: 17568997
DOI: 10.1007/s11060-007-9416-1

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17568997-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.PMID 17568997Read ↗

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.Semantic proximity Read ↗

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.Semantic proximity Read ↗

Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.Semantic proximity Read ↗

MDM2 SNP309 and SNP354 are not associated with lung cancer risk.Semantic proximity Read ↗

The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.Semantic proximity Read ↗

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.Semantic proximity Read ↗

Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.Semantic proximity Read ↗

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.